ALLO | Allogene Therapeutics, Inc.

Company profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T?) therapies for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of ?off-the-shelf? CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.